Drug intelligence / Profile preview

PEG-SMR-CLU

Development stage: Preclinical
Lead developer: Morehouse School of Medicine
Modality: Peptides
Administration: Parenteral

Overview

PEG-SMR-CLU (also known as PEG-SMRwt-CLU) is a novel investigational PEGylated peptide developed to prevent breast cancer metastasis and treat leukemia. Derived from the Secretion Modification Region (SMR) of the HIV-1 Nef protein, the peptide is modified with polyethylene glycol (PEG) at the N-terminus to improve solubility and stability, and a Clusterin (Clu)-binding peptide at the C-terminus. PEG-SMR-CLU acts by binding to and inhibiting the molecular chaperones mortalin (HSPA9) and vimentin. This inhibition blocks the release of pro-metastatic extracellular vesicles (exosomes) from cancer cells, reduces epithelial-mesenchymal transition (EMT), and induces G2/M phase cell cycle arrest. Developed by the Morehouse School of Medicine, the drug is currently in the preclinical stage of development.

Other names: PEG-SMR-CluPEG-SMRwt-CLU

Targets

VIM (Vimentin)HSPA9 (Heat shock protein family A member 9)CLU (Clusterin)

Beyond the preview

Go deeper on PEG-SMR-CLU.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PEG-SMR-CLU.

Explore the full profile